Overview
The Metabolic Bundle III: Next Gen combines Retatrutide and MOTS-c to enable investigation into the most comprehensive metabolic signaling frameworks currently available within the Not Labs catalog. In laboratory research settings, this pairing allows researchers to study coordinated GLP-1, GIP, and glucagon receptor signaling alongside mitochondrial-derived peptide regulation.
This bundle is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
Each component of the Metabolic Bundle III contributes a distinct advanced signaling role:
Retatrutide (15mg) — studied for its triple-agonist activity across GLP-1, GIP, and glucagon receptors in metabolic research models
MOTS-c (10mg) — investigated as a mitochondrial-derived peptide involved in intracellular metabolic regulation and mitochondrial–nuclear signaling coordination
Together, these compounds allow researchers to examine system-level metabolic signaling interactions across endocrine and mitochondrial pathways.
Research Context
Research investigations involving the Metabolic Bundle III: Next Gen commonly explore:
Advanced metabolic regulation models
Comparative studies versus single- and dual-agonist research compounds
Integrated incretin, glucagon, and mitochondrial signaling frameworks
Complex system-level metabolic pathway interaction studies
These investigations remain limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
Researchers evaluating this bundle often review the individual components — Retatrutide Peptide and MOTS-c Peptide — as well as foundational and intermediate formulations such as Metabolic Bundle I: Classic and Metabolic Bundle II: Synergy.
